Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor

StatusUnknown
PhasePhase 1
Started

Record status This record was last updated November 20, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Re-verified, no change to tracked fieldsv8
  3. Primary completion date: Aug 2023 to Dec 2024
    • Study completion date: Dec 2023 to Dec 2025
    v7
  4. Primary completion date: Aug 2022 to Aug 2023
    • Study completion date: Dec 2022 to Dec 2023
    v6
  5. Primary completion date: May 30, 2020 to Aug 2022v5 Show 4 more changesShow less
    • Study completion date: Dec 30, 2020 to Dec 2022
    • Eligibility criteria shortened, about 224 words
    • Study description shortened, about 55 words
    • Study site revised
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2, 2019 to Apr 11, 2019
    v4
  2. Start date: Feb 20, 2019 to Apr 2, 2019v3
  3. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase I study evaluating the safety and pharmacokinetics of MBS301 after intravenous administration in patients with HER-2 positive recurrent or metastatic malignant solid tumors
Trial Details
NCT Number NCT03842085
Lead Sponsor Beijing Mabworks Biotech Co., Ltd.
Conditions
(from sponsor)		 HER2-positive Recurrent or Metastatic Malignant Solid Tumor
Related terms Neoplasm Metastasis
Enrollment 34 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov